Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04405167 · ClinicalTrials.gov registry record · Phase 1
Tasquinimod for the Treatment of Relapsed or Refractory Myeloma
A Phase 1 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT04405167: Clinical Trial Phase 1 study, sponsored by University of Pennsylvania.
NCT04405167 is a Phase 1 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04405167, a Phase 1 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study is the first study of tasquinimod, an inhibitor of S100A9, in patients with multiple myeloma.
Primary Outcome
Maximum tolerated dose of single agent tasquinimod (mg).
Interventions
- DRUG Tasquinimod
- DRUG IRd chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-07-10 |
| Est. Completion | 2025-07-01 |
| Phase | Phase 1 |
Why NCT04405167 stopped before completion
NCT04405167 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 2 interventions - of which Tasquinimod is the first listed.
NCT04405167 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04405167 about?
NCT04405167 is a clinical study titled "Tasquinimod for the Treatment of Relapsed or Refractory Myeloma". This study is the first study of tasquinimod, an inhibitor of S100A9, in patients with multiple myeloma.
What is the current status of trial NCT04405167?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2020-07-10. Estimated completion is 2025-07-01.
What interventions are being tested in trial NCT04405167?
The interventions under investigation include: Tasquinimod (DRUG), IRd chemotherapy (DRUG).
Who is sponsoring clinical trial NCT04405167?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04405167's enrollment target sits among peer trials
30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI